Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

2016 ◽  
Vol 14 (4) ◽  
pp. 304-313.e6 ◽  
Author(s):  
Kathleen M. Mahoney ◽  
Susanna Jacobus ◽  
Rupal S. Bhatt ◽  
Jiaxi Song ◽  
Ingrid Carvo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma

2020 ◽  
Vol 126 (1) ◽  
pp. 73-82 ◽  
Author(s):  
Sumanta K. Pal ◽  
David F. McDermott ◽  
Michael B. Atkins ◽  
Bernard Escudier ◽  
Brian I. Rini ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Patient Reported Outcomes ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Patient Reported

A phase 2 study of the sphingosine‐1‐phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma

Cancer ◽  
2016 ◽  
Vol 123 (4) ◽  
pp. 576-582 ◽  
Author(s):  
Sumanta K. Pal ◽  
Harry A. Drabkin ◽  
James A. Reeves ◽  
John D. Hainsworth ◽  
Susan E. Hazel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Sphingosine 1 Phosphate
Sign in / Sign up

Export Citation Format

Share Document